Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NPs/PAs, pharmacists, and other HCPs involved in the diagnosis and treatment of acute lymphoblastic leukemia
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the efficacy and safety of new and emerging therapies for ALL, including immunotherapy, targeted therapies, and cellular therapies.
- Develop individualized treatment plans for patients with ALL by considering disease characteristics, treatment-related factors, and patient needs.
- Assess the role of MRD evaluation to guide prognosis and treatment planning in ALL.
- Incorporate strategies to monitor, mitigate and manage toxicities with newer therapies for ALL.
Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Autolus, Novartis, Pfizer, Kite, Takeda & Ascentage. Grant/ Research Funding: Amgen, Autolus, Novartis, Pfizer, Kite, Takeda & Ascentage
Hagop Kantarjian, MD
Professor and Chair
Samsung Distinguished University Chair in Cancer Medicine
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, Ascent-age, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Tar-get Rx, Stemline,Takeda. Grant/Research Funding: AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Novartis.
Aaron Logan, MD, PhD, MPhil
Associate Professor of Clinical Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Servier, Incircular
Rob Pieters, MD, PhD
Chief Medical Officer
Princess Máxima Center for Pediatric Oncology
Utrecht, Netherlands
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Servier, Incircular
Claire Roddie, MD, PhD
Clinical Lead, CAR T
University College London (UCL) Hospitals
Associate Professor in Haematology
UCL Cancer Institute
London, England
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Autolus, BMS, Kite/Gilead, J+J
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
